By 2030, the population in the United States aged 65 and older is expected to reach 71 million or about 20% of Americans.

A new tool, OBSCORE, is meant to better define who's at risk for obesity complications, going beyond BMI to include family ...

As the use of obesity medications, such as GLP-1 receptor agonists, continues to expand, the American College of Lifestyle Medicine (ACLM) has released a new Obesity Medications & Lifestyle Medicine ...

Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, ...

Illustration of human lymphocytes. (Ruslanas Baranauskas/Science Photo Library) Defeating obesity is rarely easy. For many ...

Can weight loss reverse heart failure? A new study shows that heart muscle cells regain strength and muscle contractions ...

OBSCORE is a data-driven tool that identifies high-risk individuals for obesity-related diseases, enhancing treatment ...

The Obesity Medicine Association’s interactive tool was designed to help clinicians practice real-world obesity-care ...

Oklahoma researchers found the hormone FGF21 targets the same brain region as GLP-1 drugs, but works by boosting metabolic ...

Increasing screen time, reduced physical activity and ultra-processed foods in everyday diet is driving childhood obesity in ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy in a ...